By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – WaferGen Biosystems today reported that its first-quarter revenues declined 10 percent year over year.

The Fremont, Calif.-based firm generated total revenues of $351,000 for the three-month period ended March 31, compared to $390,000 for the first quarter of 2010. WaferGen said that its revenues were derived from a combination of one or more of its SmartChip Systems, SmartChip Panels, and/or SmartChip Gene Expression Profiling Services.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.